1-3 of 3
Roland B. Walter
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Dual FLT3/PIM inhibitor dapolsertib (MEN1703) in acute myeloid leukemia: results from the phase 1/2 DIAMOND-01 trial

Open Access
Giovanni Martinelli, Scott R. Solomon, Sudipto Mukherjee, Armando Santoro, Stephen A. Strickland, Susana Vives, Farhad Ravandi, Roland B. Walter, Rachel J. Cook, Ewa Lech-Maranda, Maria Calbacho, Agnieszka Wierzbowska, Giovanni Marconi, Evelyn Acuña-Cruz, Isabel Cano-Ferri, Francesco Bertolini, Tomasz Rzymski, Alessandro Paoli, Giovanni Marino Merlo, Faten Koraichi Auriol, Sonia Zicari, Antonio Galleu, Ira Gupta, Pau Montesinos
Journal: Blood Neoplasia
Blood Neoplasia 100178.
https://doi.org/10.1016/j.bneo.2025.100178
Published: 2025
Includes: Supplemental data
Journal Articles

Safety of Gemtuzumab Ozogamicin with Cytarabine, Daunorubicin, and Midostaurin Induction in FLT3-Mutated AML

Open Access
Jayanshu Jain, Kelly Pugh, Shivani Handa, Kaitlyn M Dvorak-Kornaus, Qiuhong Zhao, Roland B Walter, Rachel Cook, Jennifer Saultz, Ronan Swords, Junyang Li, George S. Laszlo, Nicole R Grieselhuber, Alice S Mims, Karilyn T M Larkin, Kieran Sahasrabudhe, James S Blachly, Gregory K Behbehani, Ann-Kathrin Eisfeld, Meixiao Long, Andrew Srisuwananukorn, Kristin L Koenig, Uma Borate
Journal: Blood Neoplasia
Blood Neoplasia 100171.
https://doi.org/10.1016/j.bneo.2025.100171
Published: 2025
Includes: Supplemental data
Journal Articles

Phase 1 trial of venetoclax with cladribine, cytarabine, G-CSF, and mitoxantrone for AML and high-grade myeloid neoplasm

Open Access
Suravi Raychaudhuri, Ted A. Gooley, Allegra Rasmussen, Kim Quach, Eva Gill, Anna B. Halpern, Jacob S. Appelbaum, Cristina M. Ghiuzeli, Paul C. Hendrie, Ryan D. Cassaday, Roland B. Walter, Mary-Elizabeth M. Percival
Journal: Blood Neoplasia
Blood Neoplasia (2025) 2 (3): 100085.
https://doi.org/10.1016/j.bneo.2025.100085
Published: 2025
Includes: Supplemental data